Leaders in Pharmaceutical Business Intelligence (LPBI) Group

AI in Drug Discovery: Data Science and Core Biology @Merck &Co, Inc., @GNS Healthcare, @QuartzBio, @Benevolent AI and Nuritas

Reporters: Aviva Lev-Ari, PhD, RN and Irina Robu, PhD

Inclusion of this Scientific Report was inspired by 

2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020

https://pharmaceuticalintelligence.com/2020/02/21/2020-state-of-possible-conference-massbios-annual-meeting-march-25-26-2020-sonesta-hotel-cambridge-ma/

10:15 AM – 10:45 AM EDT
(30 Min)

Science Breakout: AI and Drug Discovery: Marrying Data Science with Core Biology

Colin HillChief Executive Officer, President, Chairman, and Co-Founder GNS Healthcare Moderator 

Juan Alvarez AVP, Computational and Structural Chemistry Merck & Co., Inc. Panelist

• Drug Target identification
• Drug Discovery – ML since 1980s
• Identify moleduces
• syntesis prediction
• physico space
• evolving proteins
• analysing data

Renée Deehan-Kenney PhD, VP, QuartzBio Precision Medicine Group Panelist

• technology enable company clinical data analysis of data clical trials 
• ML prior knowledge
• network biology 
• drive inside 
• MOA prioritize indications 

Rachel Hodos Senior AI Scientist Benevolent AI Panelist

Nora Khaldi Founder and CSO Nuritas Panelist